コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 M) was associated with the highest uptake of yttrium.
2 njugates were 39 hr for indium and 46 hr for yttrium.
3 ositioned and automatically loaded with a 90-yttrium, 0.014-inch source wire that was 29 mm in length
4 plantation, the use of radionuclides such as yttrium 90 (90Y) and copper 67 (67Cu), and the developme
5 valuation of the safety and effectiveness of yttrium 90 (90Y)-labeled anti-Id and shared Id (sId) MoA
6 survival when the beta-emitting radionuclide yttrium 90 instead of the alpha-emitting radionuclide (2
7 tor of poor survival in patients who undergo yttrium 90 radioembolization for unresectable liver-domi
10 he available data for radioembolization with yttrium 90 suggest that this is a potential new option f
11 des with high energy beta emissions, such as yttrium 90, and on strategies to optimize access of anti
12 ing beads, and radioembolization with use of yttrium 90, inflict lethal insult to tumors while preser
13 combined modality immunotherapy (CMIT) with yttrium (90)Y-DOTA-peptide-Lym-1 radioimmunotherapy (RIT
16 m the phase III First-Line Indolent Trial of yttrium-90 ((90)Y) -ibritumomab tiuxetan in advanced-sta
17 (FL), to evaluate the safety and efficacy of yttrium-90 ((90)Y) ibritumomab tiuxetan given as consoli
18 study compares the novel radioimmunotherapy yttrium-90 ((90)Y) ibritumomab tiuxetan with a control i
19 atients who underwent radioembolization with yttrium-90 ((90)Y) microspheres prior to resection or tr
20 I trial evaluated the safety and efficacy of yttrium-90 ((90)Y)-ibritumomab tiuxetan in patients with
23 aluated the safety and efficacy of combining yttrium-90 (90Y) ibritumomab tiuxetan with high-dose car
25 eutic potential of the beta-emitting isotope yttrium-90 (t1/2, 64 hours) conjugated to the C6.5K-A di
26 udy was to assess the efficacy and safety of yttrium-90 (Y) radioembolization for treating hepatic me
28 dioactive micron-sized particles loaded with yttrium-90 (Y90) inside the blood vessels that supply a
31 8) to deplete peripheral blood B cells, then yttrium-90 ibritumomab tiuxetan (0.4 mCi/kg; maximum, 32
34 moembolization, transarterial chemoinfusion, yttrium-90 microsphere radioembolization, and sorafenib.
35 cted patients with hepatocellular carcinoma, yttrium-90 microsphere treatment is safe and well tolera
36 ized controlled trial is warranted comparing yttrium-90 microsphere treatment with transarterial chem
37 atients were selected from a database of 108 yttrium-90 microsphere-treated patients and were staged
44 ning first-line chemotherapy with SIRT using yttrium-90 resin microspheres in patients with metastati
45 tive internal radiation therapy (SIRT) using yttrium-90 resin microspheres to standard fluorouracil,
47 (SIR Spheres)--containing the beta-emitter, yttrium-90--into the arterial supply of the liver can ca
48 rated that 400 microCi (14.8 MBq) or more of yttrium-90-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra
49 ty, tolerability, dosimetry, and efficacy of yttrium-90-labelled anti-CD22 epratuzumab tetraxetan ((9
50 ) by intra-arterial injection of radioactive yttrium-90-loaded microspheres is increasingly used for
59 sule opacification (PCO) and neodymium-doped yttrium aluminium garnet (Nd:YAG) capsulotomy rate of a
60 soliton-like pulse compression in a mm-long yttrium aluminium garnet crystal with no additional disp
61 negative effect of Nd: Yag (Neodymium-doped: Yttrium Aluminium Garnet) laser capsulotomy on the intra
62 rnet laser to be more efficient than holmium:yttrium-aluminium-garnet energy, but current erbium:yttr
70 A 532 nm frequency doubled neodymium-doped yttrium aluminum garnet (ND:YAG) laser was used to creat
72 ration was stimulated in vivo with a Holmium:yttrium aluminum garnet laser (2.12 microm), free electr
73 derwent percutaneous Biosense-guided holmium:yttrium aluminum garnet LMR to areas of viable but ische
74 llow-emitting phosphor, such as cerium-doped yttrium aluminum garnet or (YAG):Ce(3+), coupled with a
75 copic therapy, including formalin, neodymium/yttrium aluminum garnet, argon and potassium titanyl pho
76 ping; carbon dioxide (CO2); and erbium-doped:yttrium, aluminum, and garnet (Er:YAG) laser techniques
77 itched, frequency-doubled Nd:YAG (neodymium, yttrium, aluminum, garnet) laser operating at 532 nm to
78 ith a single application of either an erbium:yttrium-aluminum-garnet (Er:YAG) (2,940-nm) laser or a d
79 ifferent photoablative dental lasers, erbium:yttrium-aluminum-garnet (Er:YAG) and diode, for the trea
81 ventional ultrasonic scaler versus an erbium:yttrium-aluminum-garnet (Er:YAG) laser on titanium surfa
82 ities including carbon dioxide (CO2), erbium:yttrium-aluminum-garnet (Er:YAG), pulsed dye (PDL), and
85 Animals then underwent TMR with a holmium:yttrium-aluminum-garnet (holmium:YAG) laser (n = 5), TMI
86 r capsular opacification and neodymium-doped yttrium-aluminum-garnet (YAG) laser capsulotomy, and sur
87 Medicare beneficiary proximity to his or her yttrium-aluminum-garnet (YAG) laser capsulotomy-providin
89 silluminator, 488-nm argon-ion laser, 532-nm yttrium-aluminum-garnet (YAG) laser, blue fluorescent li
90 trials of alternative devices using holmium:yttrium-aluminum-garnet and eximer lasers are underway.
91 ery, 35.6% of patients underwent a neodymium:yttrium-aluminum-garnet capsulotomy in the iMics1 NY-60
92 significant difference in PCO and neodymium:yttrium-aluminum-garnet capsulotomy rate 3 years after s
94 s (57.9%), 9 eyes (47.4%) required neodymium-yttrium-aluminum-garnet capsulotomy, and 3 eyes (15.8%)
95 ave demonstrated that a Q-switched neodymium:yttrium-aluminum-garnet dermatology laser kills larval m
96 lculated the modulation transfer function of yttrium-aluminum-garnet doped with cerium, anthracene, a
98 tle evidence that using a diode or neodymium:yttrium-aluminum-garnet laser adds clinical value over a
99 he introduction of the side-firing neodymium:yttrium-aluminum-garnet laser in the early 1990s laser p
100 er-diameter optic fiber coupled to a holmium:yttrium-aluminum-garnet laser or a 400-micrometer-diamet
101 t, including thermal ablation with neodymium:yttrium-aluminum-garnet laser, argon plasma coagulation,
103 the combination of carbon dioxide and erbium:yttrium-aluminum-garnet lasers to achieve improved resul
105 chial amyloidosis required Nd:YAG (neodymium:yttrium-aluminum-garnet) laser therapy for obstructive s
106 3)/K reduction system was used to synthesize yttrium analogues of 2 and 3, {[(Me(3)Si)(2)N](2)(THF)Y}
107 cage complexes, and their doped diamagnetic yttrium analogues, in which competing relaxation pathway
108 d trivalent rare earth metal ions containing yttrium and all naturally abundant lanthanide metals are
110 tly faster than CHX-A' without releasing the yttrium and showed the lowest uptake by bone of any of t
111 d after membrane modification with RBS using yttrium and tungstate ions (Y(3+) and WO4(2-)) as ion pr
112 tent (defined as the sum of the lanthanides, yttrium, and scandium) for ashes derived from Appalachia
113 arsinidene complexes are described, and the yttrium-arsenic bonding is analyzed by density functiona
117 matic N-heterocycle mediated by scandium and yttrium benzyl complexes supported by a ferrocene 1,1'-d
118 gnized as forming very stable complexes with yttrium but also limited in usage because of slow Y(III)
120 y (DFT) methods are employed to examine this yttrium carbide cluster in certain family members, Y(2)C
121 iled study on the size and shape of isolated yttrium carbide clusters in different fullerene cages.
123 its enantiomeric binding generality, binding yttrium chelates in both Lambda(deltadeltadeltadelta) an
125 e (2) with pendent donor groups as potential yttrium chelators for radioimmunotherapy (RIT) have been
126 strating a large reduction in bone-deposited yttrium, compared with (90)Y-hLL2 agents prepared with o
128 rically pure but different monomers using an yttrium complex as initiator proceeds readily at room te
129 amics of alkene binding to the primary alkyl yttrium complex Cp(2)YCH(2)CH(2)CH(CH(3))(2) (2) depend
130 onal for reproduction of the geometry of the yttrium complex was validated by comparison with the exp
131 of NO by the recently discovered (N(2))(3-) yttrium complex {[(Me(3)Si)(2)N](2)(THF)Y}(2)(micro(3)-e
134 ing in situ between the oxidized and reduced yttrium complexes resulted in a change in the rate of po
136 Li vacancy is oxidized for both pure LZO and yttrium-doped LZO, which leads to a small-polaron hole.
137 ion and relithiation were achieved within an yttrium-doped LZO/carbon composite cathode that exhibite
139 tructures of antibody 2D12.5 Fab bound to an yttrium-DOTA analogue and separately to a gadolinium-DOT
140 onoclonal antibody (mAb) 2D12.5 specific for yttrium-DOTA, and the chase was Y-DOTA-human transferrin
141 silver, tungsten, heavy rare earth elements (yttrium, europium, gadolinium, terbium, dysprosium, holm
144 antibodies, (131)iodine-tositumomab and (90)yttrium-ibritumomab tiuxetan, were FDA-approved more tha
146 eport on a multicenter phase II trial of (90)yttrium-ibritumomab-tiuxetan ((90)YIT) as first-line sta
147 nalogous synthetic method was attempted with yttrium in arene solvents, the previously characterized
148 for statistical differences in the uptake of yttrium in bone and washed bone when either the DOTA or
149 roduct, 2IT-BAD-Lym-1, was labeled in excess yttrium in various buffers over a range of concentration
153 spin Seebeck effect (LSSE) in the classic Pt/yttrium iron garnet (YIG) system and its association wit
156 g all the possible materials, single-crystal yttrium iron garnet has shown up recently as a promising
157 he structure of the multilayer assemblies of yttrium iron garnet nanoparticles (YIG) with polyelectro
158 indicator composed of a bismuth-substituted yttrium iron garnet thin film, and visualizes the magnet
159 n wave absorber is demonstrated comprising a yttrium iron garnet waveguide partially covered by gold.
160 si-shaped magnonic majority gate composed of yttrium iron garnet with a partially metallized surface.
162 a temperature gradient across a thin film of yttrium iron garnet, an insulating ferrimagnet, and form
165 cer were treated with repeated cycles of (90)yttrium-labeled tetraazacyclododecane-tetraacetic acid m
166 ds CHX-B" and CHX-B' were not acceptable for yttrium labeling of antibody because of their high and p
168 enerating the second harmonic of a neodymium-yttrium-lithium-fluoride laser at a wavelength of 527 na
171 R2* measurements of the 2% SPIO-labeled yttrium microsphere concentration were well correlated w
172 R2*-based measurements of 2% SPIO-labeled yttrium microsphere delivery were well correlated with i
173 , efficacy, and prognostic factors for (90)Y-yttrium microsphere radioembolization of unresectable li
176 doses of 5, 10, 15, or 20 mg 2% SPIO-labeled yttrium microspheres were infused into 24 rats (six rats
178 hanges in the electronic environment at each yttrium nuclide in the (Y(3)N)(6+) cluster (more than 20
180 ted wastewaters containing varying levels of yttrium or europium (10, 50, and 100 ppm), and the extra
181 erfine transition of europium ion dopants in yttrium orthosilicate ((151)Eu(3+):Y2SiO5) using optical
182 PET scanner uses 4.2 x 6.3 x 30 mm lutetium yttrium orthosilicate (LYSO) crystals grouped in 9 x 6 b
183 odules each with 3 x 4 cerium-doped lutetium yttrium orthosilicate crystal blocks, each consisting of
185 nium orthosilicate and cerium-doped lutetium-yttrium orthosilicate) that give VISTA machines a DOI co
187 eport the implementation of amorphous indium yttrium oxide (a-IYO) as a thin-film transistor (TFT) se
188 ssay used europium-doped streptavidin-coated yttrium oxide (YO(x)) or polystyrene (PS) microspheres t
189 m-thick amorphous film of tantalum oxide and yttrium oxide with an yttrium-to-tantalum atomic fractio
190 hrough a porous matrix containing copper and yttrium oxides to subsequently act as catalytic sites fo
191 lts from a new PET/CT scanner using lutetium-yttrium oxyorthosilicate (LYSO) crystals for the PET com
192 ional scanner with the scintillator lutetium-yttrium oxyorthosilicate and a system timing resolution
193 and comprises 180 blocks of 13 x 13 lutetium yttrium oxyorthosilicate crystals (1.24 x 1.4 x 9.5 mm(3
194 layer-offset arrays of cerium-doped lutetium-yttrium oxyorthosilicate crystals read out by silicon ph
196 m the phenyl ring to the pyridine ring of an yttrium pyridyl complex supported by a 1,1'-ferrocene di
197 stem showed the opposite behavior to that of yttrium, revealing a metal-based dependency on the rate
200 peutic efficacy of (131)I-IMP-R4-RS7 and (90)yttrium-RS7 were equivalent, and both agents yielded sig
204 rmed to evaluate the proposed mechanism of a yttrium-salen complex-catalyzed acylation of secondary a
207 f lasers, most recently the erbium, chromium:yttrium-scandium-gallium-garnet (Er,Cr:YSGG) laser.
209 d by high-temperature sintering of compacted yttrium silicate powders doped with Pr(3+) and Li(+).
211 ithium disilicate [LD]) and a dense sintered yttrium-stabilized zirconia (YZ) were obtained from the
212 ved by supporting the CeO(2) thin film on an yttrium-stabilized zirconia substrate using a simulated
213 CHX-B' were not acceptable for labeling with yttrium, the CHX-A' and CHX-A" were suitable, indicating
214 of tantalum oxide and yttrium oxide with an yttrium-to-tantalum atomic fraction of 14% was prepared
215 ted by seawater-like rare-earth element plus yttrium trace element signatures of the metacarbonates,
216 We report the reductive coupling of NO by an yttrium-tricopper complex generating a trans-hyponitrite
217 is of 5-amino-4-carboxamidothiazoles 1 by an yttrium-triflate-catalyzed reaction of thiocarboxylic ac
218 acids known to enhance isotacticity, such as yttrium trifluoromethanesulfonate (Y(OTf)(3)) and ytterb
220 ifferences manifested as significantly lower yttrium uptake in bone and cortical bone over a 10-d per
222 mium (Pr), neodymium (Nd), samarium (Sm), or yttrium (Y)] into an epitaxial strontium titanate oxide
223 d radiometal trap for a radiolabeled ligand (yttrium[Y]-DOTA) captured by a very high-affinity anti-Y
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。